GT
TPTX

Glenmede Trust’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Glenmede Trust’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-28
Closed -$2K – 2461
2020
Q3 		$2K Buy
28
+11
+65% +$766 ﹤0.01% 2308
2020
Q2 		$1K Buy
+17
New +$981 ﹤0.01% 2410

Other funds holding TPTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Glenmede Trust's TPTX Position: Q4 2020 in Review

Glenmede Trust sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q4 2020, closing a stake of 28 shares — an estimated $2K sold.

Glenmede Trust first reported a position in TPTX in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q3 2020. 193 funds tracked by Wall St. Rank hold TPTX as of Q4 2020.

  • Glenmede Trust reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 28 Turning Point Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $2K.
  • Glenmede Trust first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Glenmede Trust's Turning Point Therapeutics, Inc. Common Stock position peaked at $2K in Q3 2020.
  • 193 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.